These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 18510103)

  • 21. From Protein Structure to Small-Molecules: Recent Advances and Applications to Fragment-Based Drug Discovery.
    Ferreira LG; Andricopulo AD
    Curr Top Med Chem; 2017; 17(20):2260-2270. PubMed ID: 28240184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening Ligands by X-ray crystallography.
    Davies DR
    Methods Mol Biol; 2014; 1140():315-23. PubMed ID: 24590727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Library Design Strategies To Accelerate Fragment-Based Drug Discovery.
    Troelsen NS; Clausen MH
    Chemistry; 2020 Sep; 26(50):11391-11403. PubMed ID: 32339336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lead generation and examples opinion regarding how to follow up hits.
    Orita M; Ohno K; Warizaya M; Amano Y; Niimi T
    Methods Enzymol; 2011; 493():383-419. PubMed ID: 21371599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico fragment-based drug design.
    Konteatis ZD
    Expert Opin Drug Discov; 2010 Nov; 5(11):1047-65. PubMed ID: 22827744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
    Hennig M; Ruf A; Huber W
    Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
    Li Q; Kang C
    Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The SeeDs approach: integrating fragments into drug discovery.
    Hubbard RE; Davis B; Chen I; Drysdale MJ
    Curr Top Med Chem; 2007; 7(16):1568-81. PubMed ID: 17979768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fragment based drug discovery using fluorescence correlation: spectroscopy techniques: challenges and solutions.
    Hesterkamp T; Barker J; Davenport A; Whittaker M
    Curr Top Med Chem; 2007; 7(16):1582-91. PubMed ID: 17979769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Designing a diverse high-quality library for crystallography-based FBDD screening.
    Tounge BA; Parker MH
    Methods Enzymol; 2011; 493():3-20. PubMed ID: 21371585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists.
    Wu B; Barile E; De SK; Wei J; Purves A; Pellecchia M
    Curr Top Med Chem; 2015; 15(20):2032-42. PubMed ID: 25986689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in fragment-based drug discovery platforms.
    Orita M; Warizaya M; Amano Y; Ohno K; Niimi T
    Expert Opin Drug Discov; 2009 Nov; 4(11):1125-44. PubMed ID: 23480433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fragment library screening and lead characterization using SPR biosensors.
    Danielson UH
    Curr Top Med Chem; 2009; 9(18):1725-35. PubMed ID: 19929838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fragment-based drug discovery-the importance of high-quality molecule libraries.
    Bon M; Bilsland A; Bower J; McAulay K
    Mol Oncol; 2022 Nov; 16(21):3761-3777. PubMed ID: 35749608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Native State Mass Spectrometry, Surface Plasmon Resonance, and X-ray Crystallography Correlate Strongly as a Fragment Screening Combination.
    Woods LA; Dolezal O; Ren B; Ryan JH; Peat TS; Poulsen SA
    J Med Chem; 2016 Mar; 59(5):2192-204. PubMed ID: 26882437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fragment based drug design: from experimental to computational approaches.
    Kumar A; Voet A; Zhang KY
    Curr Med Chem; 2012; 19(30):5128-47. PubMed ID: 22934764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
    Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficiency of hit generation and structural characterization in fragment-based ligand discovery.
    Larsson A; Jansson A; Åberg A; Nordlund P
    Curr Opin Chem Biol; 2011 Aug; 15(4):482-8. PubMed ID: 21724447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.